{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:07:13Z","timestamp":1779246433517,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR225"],"award-info":[{"award-number":["TRR225"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["326998133"],"award-info":[{"award-number":["326998133"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119275","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:54:23Z","timestamp":1774673663000},"page":"119275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An alginate-based 3D cell culture model as a useful tool for melanoma drug testing"],"prefix":"10.1016","volume":"198","author":[{"given":"Carolin","family":"Eckert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelin","family":"Sandor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tannaz","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Arkudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Kengelbach-Weigand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-394X","authenticated-orcid":false,"given":"Anja","family":"Bosserhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119275_bib1","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.3390\/cancers14194652","article-title":"Melanoma management: from epidemiology to treatment and latest advances","volume":"14","author":"Lopes","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119275_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-11-2197","article-title":"Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma","volume":"18","author":"Luke","year":"2012","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119275_bib3","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119275_bib4","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119275_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119275_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000137714","article-title":"Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results","volume":"31","author":"Egberts","year":"2008","journal-title":"Onkologie"},{"key":"10.1016\/j.biopha.2026.119275_bib7","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119275_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119275_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/clpt.2013.197","article-title":"Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies","volume":"95","author":"Jang","year":"2014","journal-title":"Clin. Pharmacol. & Ther."},{"key":"10.1016\/j.biopha.2026.119275_bib10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.14694\/EdBook_AM.2012.32.189","article-title":"Mechanisms of resistance to mitogen-activated protein kinase pathway inhibition in BRAF-mutant melanoma","author":"Goetz","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.biopha.2026.119275_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184484","article-title":"Long-term vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with EGFR expression","volume":"20","author":"Moln\u00e1r","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119275_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188754","article-title":"Targeting EGFR in melanoma \u2013 The sea of possibilities to overcome drug resistance","volume":"1877","author":"Pastwi\u0144ska","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"key":"10.1016\/j.biopha.2026.119275_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"Normanno","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119275_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119275_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/onc.2017.391","article-title":"Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition","volume":"37","author":"Dietrich","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2026.119275_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcdb.2016.07.012","article-title":"The role of wild type RAS isoforms in cancer","volume":"58","author":"Zhou","year":"2016","journal-title":"Semin. Cell & Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119275_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2026.119275_bib18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","article-title":"KRAS as a Therapeutic Target","volume":"21","author":"McCormick","year":"2015","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2026.119275_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging Ras Back in the Ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.119275_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.110264","article-title":"Comparison of 2D and 3D cell culture models for cell growth, gene expression and drug resistance","volume":"107","author":"Fontoura","year":"2020","journal-title":"Materials Science Engineering C"},{"key":"10.1016\/j.biopha.2026.119275_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acs.biomac.7b01331","article-title":"Oxidized alginate-based hydrogels for tissue engineering applications: a review","volume":"19","author":"Reakasame","year":"2018","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2026.119275_bib22","doi-asserted-by":"crossref","first-page":"45004","DOI":"10.1088\/1758-5090\/ab98e5","article-title":"Improving alginate printability for biofabrication: establishment of a universal and homogeneous pre-crosslinking technique","volume":"12","author":"Hazur","year":"2020","journal-title":"Biofabrication"},{"key":"10.1016\/j.biopha.2026.119275_bib23","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3390\/cancers13164111","article-title":"Molecular Changes Induced in Melanoma by Cell Culturing in 3D Alginate Hydrogels","volume":"13","author":"Kappelmann-Fenzl","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119275_bib24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/cancers14010190","article-title":"3D cell culture models as recapitulators of the tumor microenvironment for the screening of anti-cancer drugs","volume":"14","author":"Barbosa","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119275_bib25","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.3390\/ijms222212200","article-title":"3D cell culture systems: tumor application, advantages, and disadvantages","volume":"22","author":"Habanjar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119275_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bprint.2024.e00384","article-title":"An alginate-cellulose based bioink mimics the viscoelastic features of the melanoma microenvironment and its influence on cell cycle and invasion","volume":"46","author":"Eckert","year":"2025","journal-title":"Bioprinting"},{"key":"10.1016\/j.biopha.2026.119275_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202107993","article-title":"A new printable alginate\/hyaluronic acid\/gelatin hydrogel suitable for biofabrication of in vitro and in vivo metastatic melanoma models","volume":"32","author":"Schmid","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biopha.2026.119275_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1242\/jcs.195164","article-title":"A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level","volume":"130","author":"Koh","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.biopha.2026.119275_bib29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/pcmr.12801","article-title":"Role of melanoma inhibitory activity in melanocyte senescence","volume":"32","author":"Feuerer","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.biopha.2026.119275_bib30","first-page":"3042","article-title":"Development of a model system to analyze chondrogenic differentiation of mesenchymal stem cells","volume":"6","author":"Ruedel","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2026.119275_bib31","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1021\/acs.biomac.2c01282","article-title":"How to determine a suitable alginate for biofabrication approaches using an extensive alginate library?","volume":"24","author":"Karakaya","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2026.119275_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-019-04002-1","article-title":"Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma","volume":"85","author":"Kichenadasse","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119275_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jpba.2009.02.008","article-title":"Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice","volume":"49","author":"Blanchet","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.biopha.2026.119275_bib34","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1535-7163.MCT-10-0073","article-title":"Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy","volume":"9","author":"Augustine","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119275_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2026.119275_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13741","article-title":"Splicing control by PHF5A is crucial for melanoma cell survival","volume":"58","author":"Mei\u00dfgeier","year":"2025","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2026.119275_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10334-005-0013-z","article-title":"Microscopic images of intraspheroidal pH by 1H magnetic resonance chemical shift imaging of pH sensitive indicators","volume":"18","author":"Alvarez-P\u00e9rez","year":"2005","journal-title":"MAGMA"},{"key":"10.1016\/j.biopha.2026.119275_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1297644","article-title":"Spheroid size influences cellular senescence and angiogenic potential of mesenchymal stromal cell-derived soluble factors and extracellular vesicles","volume":"11","author":"Rovere","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119275_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/cancers10060157","article-title":"Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119275_bib40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119275_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119275_bib42","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/jcp.26052","article-title":"Three-dimensional cell culture models for anticancer drug screening: Worth the effort?","volume":"233","author":"Verjans","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119275_bib43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1593\/neo.10414","article-title":"Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma","volume":"12","author":"Tap","year":"2010","journal-title":"Neoplasia (N. Y. N. Y. )"},{"key":"10.1016\/j.biopha.2026.119275_bib44","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-10-0646","article-title":"RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models","volume":"70","author":"Yang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119275_bib45","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17460441.2016.1201057","article-title":"The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma","volume":"11","author":"Kim","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119275_bib46","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1517\/14656566.2012.737780","article-title":"Vemurafenib for the treatment of melanoma","volume":"13","author":"Jordan","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119275_bib47","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/jid.2013.6","article-title":"Vemurafenib induces senescence features in melanoma cells","volume":"133","author":"Haferkamp","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2026.119275_bib48","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.18632\/oncotarget.9023","article-title":"Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model","volume":"7","author":"Danysh","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119275_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119275_bib50","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119275_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053708","article-title":"AlgiMatrix\u2122 Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies","volume":"8","author":"Godugu","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2026.119275_bib52","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-15-0963","article-title":"Hypoxia-driven mechanism of vemurafenib resistance in melanoma","volume":"15","author":"Qin","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119275_bib53","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cells12050759","article-title":"3D Spheroid Configurations Are Possible Indictors for Evaluating the Pathophysiology of Melanoma Cell Lines","volume":"12","author":"Ohguro","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119275_bib54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/ijms23031166","article-title":"Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models","volume":"23","author":"Filipiak-Duliban","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119275_bib55","doi-asserted-by":"crossref","DOI":"10.1007\/s10616-020-00440-5","article-title":"Three-dimensional multicellular cell culture for anti-melanoma drug screening: focus on tumor microenvironment","volume":"73","author":"Saleh","year":"2021","journal-title":"Cytotechnology"},{"key":"10.1016\/j.biopha.2026.119275_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-31502-6","article-title":"Tissue-engineered 3D melanoma model with blood and lymphatic capillaries for drug development","volume":"8","author":"Bourland","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119275_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.249","article-title":"Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing","volume":"4","author":"V\u00f6rsmann","year":"2013","journal-title":"Cell Death Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:33:55Z","timestamp":1779244435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":57,"alternative-id":["S0753332226003082"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119275","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An alginate-based 3D cell culture model as a useful tool for melanoma drug testing","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119275"}}